Skip to content
Search

Latest Stories

MHRA drug alert for Finasteride 5mg tablets

The Medicines and Healthcare products Regulatory Agency (MHRA) today issued a class 4 drug alert for 30 batches of Finasteride 5mg tablets.

Dr Reddy’s Laboratories (UK) has informed the government agency that Patient Information Leaflet (PIL) for these batches is missing the special warning precautions identified from post-marketing experience that is documented in the Summary of Product Characteristics (SmPC).


The change concerns the addition of the following in Section 4.4 Special warnings and precautions for use: “Mood alterations and depression: Mood alterations including depressed mood, depression and, less frequently, suicidal ideation have been reported in patients treated with finasteride 5 mg. Patients should be monitored for psychiatric symptoms and if these occur, the patient should be advised to seek medical advice.”

Pharmacists are asked to ensure that the patients are aware of any missing information. Any patients who notice the symptoms must seek immediate medical advice.

Product details:

Batch NumberExpiry datePack SizeFirst Distributed
C706092Nov 20202821 Feb 2018
C706093Nov 20202821 Feb 2018
C706094Nov 20202819 Mar 2018
C706095Nov 20202801 May 2018
C800262Dec 20202819 Mar 2018
C800263Dec 20202819 Mar 2018
C800264Dec 20202819 Mar 2018
C800483Dec 20202801 May 2018
C800484Dec 20202819 Mar 2018
C800485Dec 20202801 May 2018
C800486Dec 20202806 Apr 2018
C800506Jan 20212810 May 2018
C800507Dec 20202806 Apr 2018
C800508Dec 20202810 May 2018
C800509Jan 20212810 May 2018
C800510Jan 20212801 May 2018
C804932Jun 20212820 Sep 2018
C804933Jun 20212820 Sep 2018
C804934Jun 20212810 Oct 2018
C804935Jun 20212820 Sep 2018
C804936Jun 20212820 Sep 2018
C804937Jun 20212820 Sep 2018
C804938Jun 20212820 Sep 2018
C804939Jun 20212816 Oct 2018
C804940Jun 20212831 Oct 2018
C804941Jun 20212831 Oct 2018
C806744Oct 20212818 Mar 2019
C806745Oct 20212818 Mar 2019
C806746Oct 20212818 Mar 2019
C806747Oct 20212818 Mar 2019

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less